Plastic surgery

Medications for obesity treatment: how do they act on FAT?

June 27, 2024
By Fernando Amato

Anti-obesity medications show direct effects in reducing visceral fat and adipose tissue inflammation, promoting metabolic health.

Medical anti-obesity treatments: Direct impact on adipose tissue

Over the past few years, several medications have been developed for the treatment of obesity. Some of these medications are already used in clinical practice, while others are under development. These medications primarily work by reducing food intake or fat absorption, but many also show specific effects on adipose tissue.

Highlights of the Obesity Treatment Article:

🔬 Several anti-obesity medications significantly reduce fat mass, especially visceral fat.
📉 Orlistat is known to decrease fat absorption, while GLP-1 receptor agonists reduce appetite.
🔥 Some medications increase thermogenesis, promoting fat burning.
🧬 GLP-1 RAs and GLP-1/GIP co-agonists promote adipocyte differentiation and reduce inflammation.
💊 Future therapies, including GLP-1/GIP/glucagon tri-agonists, may offer even more potent effects in fat reduction.

Introduction to obesity treatment

The prevalence of obesity has, however, increased worldwide, associated with high risks of type 2 diabetes, hypertension, coronary heart disease, and premature death. Therefore, given the seriousness of this condition, it is crucial to develop effective therapeutic strategies to reduce the burden of obesity. Additionally, new medications have recently been developed, and others are on the way, with some of them showing direct effects on adipose tissue.

Orlistat for obesity treatment

Orlistat is a gastric and pancreatic lipase inhibitor that reduces fat absorption. However, in clinical studies, orlistat showed a significant reduction in visceral fat compared to placebo. Although it does not increase energy expenditure in humans, orlistat influences lipid metabolism in adipose tissue and promotes the reduction of adipocyte size.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (GLP-1 RAs) are antidiabetic treatments that also promote weight loss. Thus, they reduce appetite and food intake, inducing a significant reduction in fat mass, especially visceral fat. In studies, these medications have been shown to promote adipocyte differentiation and reduce inflammation in adipose tissue.

READ Abdominal Dermolipectomy or Abdominoplasty with or without Liposuction

GLP-1/GIP Co-agonists

Tirzepatide, a GLP-1/GIP co-agonist, has demonstrated significant reduction in visceral fat mass in clinical trials. This medication can also increase thermogenesis and fat oxidation in adipose tissue. Studies indicate that tirzepatide can promote the “browning” of adipose tissue, increasing the expression of thermogenesis-related proteins.

GLP-1/GIP/Glucagon Tri-agonists

GLP-1/GIP/Glucagon tri-agonists are being developed to treat diabetes and obesity. These medications have shown greater body weight reduction and increased energy expenditure in animal models. The activation of glucagon receptors increases thermogenesis, contributing to weight loss.

Conclusion

Medical treatments for obesity not only reduce food intake and fat absorption but also have direct effects on adipose tissue. Medications such as orlistat, GLP-1 RAs, GLP-1/GIP co-agonists, and GLP-1/GIP/glucagon tri-agonists show promising effects in reducing fat mass and promoting metabolic health. Future studies are needed to fully understand the mechanisms of these medications in adipose tissue.

Frequently Asked Questions:

What is orlistat and how does it work?
- Orlistat is a medication that inhibits gastric and pancreatic lipases, reducing fat absorption in the intestine.
What are the main effects of GLP-1 receptor agonists?
- GLP-1 receptor agonists reduce appetite, promote satiety, and decrease fat mass, especially visceral fat.
What are GLP-1/GIP co-agonists?
- GLP-1/GIP co-agonists, such as tirzepatide, act on both GLP-1 and GIP receptors, promoting significant weight loss and increasing thermogenesis.
How do GLP-1/GIP/glucagon tri-agonists help with weight loss?
- These medications activate multiple receptors, increasing energy expenditure and promoting thermogenesis, resulting in greater body weight reduction.
Does orlistat affect thermogenesis?
- No, orlistat does not increase thermogenesis, but it influences lipid metabolism in adipose tissue.
What is the impact of GLP-1 receptor agonists on adipose tissue inflammation?
- They reduce inflammation in adipose tissue, promoting adiponectin production and reducing pro-inflammatory cytokines.
How do anti-obesity medications affect visceral fat?
- Many medications, such as GLP-1 receptor agonists and GLP-1/GIP co-agonists, significantly reduce visceral fat.
What is adiponectin and how is it affected by anti-obesity treatments?
- Adiponectin is a protein that improves insulin sensitivity. Anti-obesity treatments, such as GLP-1 RAs, increase adiponectin levels in the blood.
What are the effects of anti-obesity treatments on adipocyte differentiation?
- Treatments such as GLP-1 RAs promote adipocyte differentiation, contributing to metabolic health.
Should I consult a specialist before starting anti-obesity treatment?
- Yes, it is essential to consult a specialist, such as Dr. Fernando Amato, to determine the most appropriate and safe treatment for your specific case.